United Therapeutics Q3: Tyvaso DPI lifts sales 4%, but a $130M R&D charge cuts net income 24%

The quarter in numbers

United Therapeutics reported third-quarter 2026 total revenues of $832.5 million, up 4% from $799.5 million a year earlier. Profit moved the other way. Operating income fell to $307.8 million from $388.5 million, and net income fell 24% to $258.6 million from $338.7 million. Diluted earnings per share were $5.71 against $7.16, a 20% decline, cushioned by a lower share count (diluted weighted average shares of 45.3 million versus 47.3 million).

On our arithmetic from the income statement, operating income was about 37.0% of revenue, against about 48.6% a year earlier. Most of that gap is explained by one R&D line, discussed below. The company described the quarter as a record for revenue, and its COO said the company has 'the strongest growth outlook in our history.' Those are management characterizations, not guidance.

Tyvaso franchise: a shift between formulations

Total Tyvaso revenue rose 5% to $503.8 million. Inside that figure, the mix is moving toward the dry-powder inhaler. Tyvaso DPI sales rose 13% to $378.5 million. The company attributed this mainly to a $43.9 million increase in quantities sold and a price increase, partly offset by higher gross-to-net deductions. Nebulized Tyvaso fell 12% to $125.3 million, which the company tied mainly to a $20.0 million decline in U.S. quantities sold, partly offset by a price increase.

The company also said it believes the availability of competitive therapies negatively affected sales of Nebulized Tyvaso, Tyvaso DPI and Remodulin in the quarter. It gave no quantification of that effect.

Other products and geography

Orenitram grew 11% to $145.0 million, driven mainly by a $14.9 million increase in quantities sold and a price increase, partly offset by higher gross-to-net deductions. Remodulin, which includes infusion devices, slipped 3% to $122.0 million. Unituxin rose 9% to $52.3 million. Adcirca fell 54% to $4.5 million and 'Other' fell 29% to $4.9 million.

The business remains overwhelmingly U.S.-based. U.S. revenue was $808.5 million (versus $774.8 million), and rest-of-world revenue was $24.0 million (versus $24.7 million). Tyvaso DPI recorded $0.3 million of ROW sales, against none a year ago. Remodulin ROW sales declined to $13.5 million from $15.2 million.

Costs: the Thymmune charge and a litigation reversal

Cost of sales was essentially flat to lower at $99.1 million versus $100.9 million, a 2% decline, while revenue rose, so product-level economics were not the source of the profit squeeze.

R&D expense more than doubled to $279.2 million from $127.5 million. The driver was an 'Other' category of $130.0 million, up from $4.8 million. That category includes in-process R&D acquisition costs, and the company linked the increase mainly to its acquisition of Thymmune Therapeutics, accounted for as an asset acquisition. External R&D rose 21% to $77.1 million and internal R&D rose 20% to $61.0 million. The company also cited higher spending on manufactured organ and organ alternative projects and on cardiopulmonary treatment projects.

SG&A fell 20% to $146.4 million, but only because of an accounting item. A litigation accrual of negative $66.5 million, a reversal of a liability tied to the Sandoz matter, replaced a $0.8 million expense a year earlier. Underlying lines grew: general and administrative expense (excluding the accrual) rose 16% to $143.1 million on headcount, legal and consulting costs, and sales and marketing rose 45% to $41.0 million on headcount. Without the reversal, operating income would have been lower than the reported $307.8 million.

Below the line: tax, interest and buybacks

Other income, net rose to $34.2 million from $6.1 million, mainly on gains on equity securities. Interest income fell to $33.7 million from $46.4 million as the company sold securities to fund accelerated share repurchases. The effective tax rate rose to 31% from 23%, with income tax expense of $114.2 million versus $99.3 million. The company attributed the increase mainly to nondeductible Thymmune IPR&D expense.

Capital return was active. Under a $2.0 billion program approved in March 2026, the company ran three accelerated repurchase agreements with Citi: two in March for about $1.5 billion and one in September for about $477.6 million. In the quarter it received 215,948 shares on final settlement of the second March agreement and 719,376 shares as the initial delivery on the September agreement. It also bought 45,070 shares for $22.4 million under a Rule 10b5-1 plan, for 980,394 shares repurchased in total. The September agreement used the program's remaining authorization, with final settlement expected in the fourth quarter. In October 2026 the board approved a new program of up to $2.0 billion through October 21, 2027.

Guidance, pipeline and what to watch

The release contains no numerical financial guidance, and it names no specific clinical readouts or regulatory dates. Management's language on 'significant new opportunities across cardiopulmonary and respiratory medicine rapidly approaching' therefore cannot be tied to a calendar from this document alone.

Items the release does flag: the settlement with Liquidia Technologies, agreed in October 2026, which led to the Sandoz matter being dismissed on October 28, 2026; the fourth-quarter final settlement of the September repurchase agreement; and the 10-Q's litigation note. The key commercial question is whether Tyvaso DPI growth keeps outrunning declines in the nebulized product while competitive pressure persists. Also worth tracking is whether R&D stays elevated beyond the Thymmune charge as organ and cardiopulmonary programs scale.